Variable response to opioid treatment: Any genetic predictors within sight?

Palliative Medicine

Volumn 22, Issue 4, 2008, Pages 310-327

  Skorpen, Frank ^a   Laugsand, E A ^a   Klepstad, P ^b   Kaasa, S ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Adverse effects; Analgesia; Analgesics; Opioid; Palliative care; Pharmacogenetics

Indexed keywords

ALFENTANIL; APOLIPOPROTEIN E; BETA ARRESTIN 2; BUPRENORPHINE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE 2B7; GLYCOPROTEIN P; HYDROMORPHONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; KETOROLAC; LEVOMETHADONE; MELANOCORTIN 1 RECEPTOR; METHADONE; MORPHINE; MORPHINE 6 GLUCURONIDE; MORPHINE SULFATE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; NARCOTIC ANALGESIC AGENT; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PLACEBO; QUINIDINE; RIFAMPICIN; STAT6 PROTEIN; SUFENTANIL;

ALLELE; ANALGESIA; ANOREXIA; ANXIETY; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DYSPNEA; EUPHORIA; FATIGUE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HICCUP; HUMAN; HUNGER; MUSCLE CRAMP; NAUSEA; NONHUMAN; OPIATE ADDICTION; PAIN; PALLIATIVE THERAPY; PHARMACOGENETICS; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

ANALGESICS, OPIOID; GENETIC MARKERS; HUMANS; PAIN, INTRACTABLE; PALLIATIVE CARE; POLYMORPHISM, GENETIC;

EID: 46049118417     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269216308089302     Document Type: Review

References (81)

1. WHO. Cancer Pain Relief and Palliative Care. Geneva, Switzerland: World Health Organization, Technical Report Series No 804, 1990.
2. WHO. Cancer pain relief: With a guide to opioid availability. Geneva, Switzerland: World Health Organization, 1996.
3. Hanks, GW, Conno, F, Cherny, N, Hanna, M, Kalso, E, McQuay, HJ, et al. Morphine and alternative opioids in cancyer pain: the EAPC recommendations. Br J Cancer 2001; 84: 587-593.
4. Hanks, GW, Reid, C. Contribution to variability in response to opioids. Support Care Cancer 2005; 13: 145-152.
5. Cherny, N, Ripamonti, C, Pereira, J, Davis, C, Fallon, M, McQuay, H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19: 2542-2554.
6. Lander, ES, Linton, LM, Birren, B, Nusbaum, C, Zody, MC, Baldwin, J, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
7. Venter, JC, Adams, MD, Myers, EW, Li, PW, Mural, RJ, Sutton, GG, et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
8. Stamer, UM, Bayerer, B, Stuber, F. Genetics and variability in opioid response. European Journal of Pain 2005; 9: 101-104.
9. McQuay, HJ, Carroll, D, Faura, CC, Gavaghan, DJ, Hand, CW, Moore, RA. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990; 48: 236-244.
10. Klepstad, P, Kaasa, S, Skauge, M, Borchgrevink, PC. Pain intensity and side effects during titration of morphine to cancer patients using a fired schedule dose escalation. Acta Anaesthesiol Scand 2000; 44: 656-664.
11. Stromgren, AS, Groenvold, M, Pedersen, L, Olsen, AK, Sjogren, P. Symptomatology of cancer patients in palliative care: content validation of self-assessment questionnaires against medical records. Eur J Cancer 2002; 38: 788-794.
12. Glare, P, Walsh, D, Sheehan, D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care 2006; 23: 229-235.
13. Mercadante, S, Villari, P, Ferrera, P, Casuccio, A. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients. Eur J Pain 2006; 10: 153-159.
14. Somogyi, AA, Barratt, DT, Coller, JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81: 429-444.
15. Kasai, S, Hayashida, M, Sora, I, Ikeda, K. Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn Schmiedebergs Arch Pharmacol. 2007.
16. Lotsch, J, Skarke, C, Liefhold, J, Geisslinger, G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004; 43: 983-1013.
17. Lotsch, J, Geisslinger, G. Current evidence for a modulation of nociception by human genetic polymorphisms. Pain 2007; 132: 18-22.
18. Mogil, JS. The genetics of pain. In: Mogil, JS, (ed.) Progression in Pain Research and Management. Vol 28. IASP Press; 2004, Seattle, WA, USA.
19. Davis, MP, Homsi, J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 2001; 9: 442-451.
20. Gardiner, SJ, Begg, EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58: 521-590.
21. Stamer, UMSF. Genetic factors in pain and its treatment. Current Opinion in Anaesthesiology 2007; 20: 478-484.
22. Kilpatrick, GJ, Smith, TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 2005; 25: 521-544.
23. Holthe, M, Klepstad, P, Zahlsen, K, Borchgrevink, PC, Hagen, L, Dale, O, et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002; 58: 353-356.
24. Mackenzie, PI, Miners, JO, McKinnon, RA. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 2000; 38: 889-892.
25. Sawyer, MB, Innocenti, F, Das, S, Cheng, C, Ramirez, J, Pantle-Fisher, FH, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003; 73: 566-574.
26. Holthe, M, Rakvag, TN, Klepstad, P, Idle, JR, Kaasa, S, Krokan, HE, et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 2003; 3: 17-26.
27. Ross, JR, Rutter, D, Welsh, K, Joel, SP, Goller, K, Wells, AU, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005; 5: 324-336.
28. Coulbault, L, Beaussier, M, Verstuyft, C, Weickmans, H, Dubert, L, Tregouet, D, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006; 79: 316-324.
29. Bond, C, LaForge, KS, Tian, M, Melia, D, Zhang, S, Borg, L, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998; 95: 9608-9613.
30. Kroslak, T, Laforge, KS, Gianotti, RJ, Ho, A, Nielsen, DA, Kreek, MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 2007; 103: 77-87.
31. Lotsch, J, Skarke, C, Grosch, S, Darimont, J, Schmidt, H, Geisslinger, G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12: 3-9.
32. Skarke, C, Darimont, J, Schmidt, H, Geisslinger, G, Lotsch, J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73: 107-121.
33. Lotsch, J, Skarke, C, Wieting, J, Oertel, BG, Schmidt, H, Brockmoller, J, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 2006; 79: 72-89.
34. Klepstad, P, Rakvag, TT, Kaasa, S, Holthe, M, Dale, O, Borchgrevink, PC, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48: 1232-1239.
35. Romberg, RR, Olofsen, E, Bijl, H, Taschner, PE, Teppema, LJ, Sarton, EY, et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 2005; 102: 522-530.
36. Chou, WY, Yang, LC, Lu, HF, Ko, JY, Wang, CH, Lin, SH, et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006; 50: 787-792.
37. Chou, WY, Wang, CH, Liu, PH, Liu, CC, Tseng, CC, Jawan, B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105: 334-337.
38. Oertel, BG, Schmidt, R, Schneider, A, Geisslinger, G, Lotsch, J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006; 16: 625-636.
39. Campa, D, Gioia, A, Tomei, A, Poli, P, Barale, R. Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief. Clin Pharmacol Ther. 2007 [Epub ahead of print]
40. Lotsch, J, Geisslinger, G. Are [mu]-opioid receptor polymorphisms important for clinical opioid therapy. Trends in Molecular Medicine 2005; 11: 82-89.
41. Zubieta, JK, Heitzeg, MM, Smith, YR, Bueller, JA, Xu, K, Xu, Y, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003; 299: 1240-1243.
42. Diatchenko, L, Slade, GD, Nackley, AG, Bhalang, K, Sigurdsson, A, Belfer, I, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005; 14: 135-143.
43. Diatchenko, L, Nackley, AG, Slade, GD, Bhalang, K, Belyfer, I, Max, MB, et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 2006; 125: 216-224.
44. Kim, H, Lee, H, Rowan, J, Brahim, J, Dionne, RA. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol Pain 2006; 2: 24.
45. Rakvag, TT, Klepstad, P, Baar, C, Kvam, TM, Dale, O, Kaasa, S, et al. The Val158Met polymorphism of the human catechol-Oy-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005; 116: 73-78.
46. Bessler, H, Shavit, Y, Mayburd, E, Smirnov, G, Beilin, B. Postoperative pain, morphine consumption, and genetic polymorphism of IL-1beta and IL-1 receptor antagonist. Neurosci Lett 2006; 404: 154-158.
47. Rees, JL, Birch-Machin, M, Flanagan, N, Healy, E, Phillips, S, Todd, C. Genetic studies of the human melanocortin-1 receptor. Ann N Y Acad Sci 1999; 885: 134-142.
48. Xia, Y, Wikberg, JE, Chhajlani, V. Expression of melanocortin 1 receptor in periaqueductal gray matter. Neuroreport 1995; 6: 2193-2196.
49. Basbaum, AI, Fields, HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984; 7: 309-338.
50. Mogil, JS, Wilson, SG, Chesler, EJ, Rankin, AL, Nemmani, KV, Lariviere, WR, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A 2003; 100: 4867-4872.
51. Mogil, JS, Ritchie, J, Smith, SB, Strasburg, K, Kaplan, L, Wallace, MR, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 2005; 42: 583-587.
52. King, M, Su, W, Chang, A, Zuckerman, A, Pasternak, GW. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci 2001; 4: 268-274.
53. Wandel, C, Kim, R, Wood, M, Wood, A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 2002; 96: 913-920.
54. Thompson, SJ, Koszdin, K, Bernards, CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000; 92: 1392-1399.
55. Huwyler, J, Drewe, J, Klusemann, C, Fricker, G. Evidence for P-glycoprotein-modulated penetration, of morphine-6-glucuronide into brain capillary endothelium. Br J Pharmacol 1996; 118: 1879-1885.
56. Fromm, MF, Eckhardt, K, Li, SX, Schanzle, G, Hofmann, U, Mikus, G, et al. Loss of analgesic effect of morphine due coadministration of rifampin. Pain 1997; 72: 261-267.
57. Kharasch, ED, Hoffer, C, Whittington, D, Sheffels, P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003; 74: 543-554.
58. Reyes-Gibby, CC, Shete, S, Rakvag, T, Bhat, SV, Skorpen, F, Bruera, E, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007; 130: 25-30.
59. Hollt, V. A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics 2002; 12: 1-2.
60. Lotsch, J, Zimmermann, M, Darimont, J, Marx, C, Dudziak, R, Skarke, C, et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity. Anesthesiology 2002; 97: 814-819.
61. Park, HJ, Shinn, HK, Ryu, SH, Lee, HS, Park, CS, Kang, JH. Genetic Polymorphisms in the ABCB1 Gene and the Effects of Fentanyl in Koreans. Clin Pharmacol Ther 2006; 81: 539-546.
62. Strittmatter, WJ, Saunders, AM, Schmechel, D, Pericak-Vance, M, Enghild, J, Salvesen, GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 1977-1981.
63. Saunders, AM, Strittmatter, WJ, Schmechel, D, George-Hyslop, PH, Pericak-Vance, MA, Joo, SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
64. Laskowitz, DT, Horsburgh, K, Roses, AD. Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab 1998; 18: 465-471.
65. Smith, JD. Apolipoproteins and aging: emerging mechanisms. Ageing Res Rev 2002; 1: 345-365.
66. Packard, CJ, Westendorp, RG, Stott, DJ, Caslake, MJ, Murray, HM, Shepherd, J, et al. Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc 2007; 55: 1777-1785.
67. Liang, WS, Dunckley, T, Beach, TG, Grover, A, Mastroeni, D, Walker, DG, et al. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics 2007; 28: 311-322.
68. Kofke, WA, Blisitt, PA, Rao, H, Wang, J, Addya, K, Detre, J. Remifentanil-induced cerebral blood flow effects in normal humans: Dose and ApoE genotype. Anesthesia and Analgesia 2007; 105: 167-175.
69. Riley, J, Ross, JR, Rutter, D, Wells, AU, Goller, K, du Bois, R, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Supportive Care in Cancer 2006; 14: 56-64.
70. Heiskanen, T, Olkkola, KT, Kalso, E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64: 603-611.
71. de Leon, J, Dinsmore, L, Wedlund, P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultra-rapid metabolizers. J Clin Psychopharmacol 2003; 23: 420-421.
72. Foster, A, Mobley, E, Wang, Z. Complicated Pain Management in a CYP450 2D6 Poor Metabolizer. Pain Pract 2007; 7: 352-356.
73. Susce, MT, Murray-Carmichael, E, de Leon, J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1356-1358.
74. Jannetto, PJ, Wong, SH, Gock, SB, Laleli-Sahin, E, Schur, BC, Jentzen, JM. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. J Anal Toxicol 2002; 26: 438-447.
75. Jin, M, Gock, SB, Jannetto, PJ, Jentzen, JM, Wong, SH. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol 2005; 29: 590-598.
76. Hirota, T, Ieiri, I, Takane, H, Sano, H, Kawamoto, K, Aono, H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 2003; 31: 677-680.
77. Tremblay, PB, Kaiser, R, Sezer, O, Rosler, N, Schelenz, C, Possinger, K, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003; 21: 2147-2155.
78. 3 receptor antagonists. Pharmacogenetics 2004; 14: 271-278.
79. Max, MB, Wu, TX, Atlas, SJ, Edwards, RR, Haythornthwaite, JA, Bollettino, AF, et al. A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Mol Pain 2006; 2: 14.
80. Craft, RM. Sex differences in opioid analgesia: "from mouse to man". Clin J Pain 2003; 19: 175-186.
81. Bernard, SA, Bruera, E. Drug interactions in palliative care. J Clin Oncol 2000; 18: 1780-1799.